A phase I/II trial of TG-4010 in combination with immune checkpoint inhibitors and chemotherapy in first line, stage IV non-small cell lung cancer patients with tumor cells expressing low or undetectable levels of PD-L1

Trial Profile

A phase I/II trial of TG-4010 in combination with immune checkpoint inhibitors and chemotherapy in first line, stage IV non-small cell lung cancer patients with tumor cells expressing low or undetectable levels of PD-L1

Planning
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs TG 4010 (Primary) ; Immunomodulators
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 20 Mar 2017 According to a Transgene media release, company is in prospective discussion with a pharma to conduct this trial and first patient expected to be enrolled towards the end of 2017 in this trial.
    • 05 Sep 2016 According to a Transgene media release, phase II trial is expected to be initiated in first half of 2017.
    • 08 Mar 2016 According to a Transgene media release, this trial is expected to be initiated in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top